60 F. Supp. 3d 1289
M.D. Fla.2015Background
- Plaintiffs Lori and Matthew Byrnes sue Medtronic over injuries Lori suffered after receiving Infuse, a Class III FDA‑approved bone graft device, implanted off‑label (posterior lumbar fusion without the LT‑Cage).
- Infuse was approved via the PMA process for a specific anterior lumbar interbody fusion and the FDA warned about adverse events and off‑label use; Medtronic sold components separately and allegedly promoted off‑label uses.
- Lori alleges claims including fraud/fraud in inducement, failure to warn, design defect, strict products liability (misrepresentation), negligence, and breach of express warranty; Matthew asserts loss of consortium.
- Medtronic moved to dismiss, arguing the Medical Device Amendments’ express preemption (21 U.S.C. § 360k) and FDCA implied preemption (21 U.S.C. § 337(a)/Buckman) bar most claims, and that fraud claims lack Rule 9(b) particularity.
- The Court held many claims preempted (or impliedly preempted) but recognized a narrow non‑preempted space for claims based on voluntary, affirmative false off‑label statements; several claims were dismissed with prejudice while others were dismissed without prejudice and Plaintiffs were granted leave to amend limited claims.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether state law claims are expressly preempted by the MDA (Riegel) | Byrnes contends some claims (e.g., fraud based on affirmative misrepresentations, express warranty) can survive because they target off‑label promotion and voluntary statements rather than FDA requirements | Medtronic argues PMA approval creates device‑specific federal requirements that preempt state claims that would impose different or additional safety/effectiveness requirements | Court: PMA approval satisfies Riegel’s first prong; design defect and failure‑to‑warn claims are expressly preempted; some claims based on affirmative false off‑label statements are not preempted |
| Whether claims are impliedly preempted under Buckman/§ 337(a) where they effectively enforce FDCA duties | Byrnes contends her state claims (e.g., fraudulent misrepresentation, express warranty) arise independently from state law and do not merely enforce FDCA reporting/labeling duties | Medtronic contends allegations that seek to enforce FDA reporting/label duties or merely assert off‑label promotion without misrepresentations are impliedly preempted | Court: Claims premised on failure to report adverse events or mere truthful off‑label promotion are impliedly preempted; affirmative false promotion claims are not impliedly preempted |
| Sufficiency of fraud pleadings (Rule 9(b)) | Byrnes alleges fraudulent concealment/promotion but did not identify specific misrepresentations or reliance by the surgeon | Medtronic argues Rule 9(b) requires particularized allegations of who said what, when, to whom, and reliance/cause | Court: Plaintiffs’ fraud/affirmative‑misrepresentation allegations fail Rule 9(b); dismissal without prejudice and leave to amend allowed to plead particulars |
| Whether breach of express warranty survives preemption | Byrnes alleges Medtronic made voluntary affirmative warranties during off‑label promotion that induced use | Medtronic argues any warranty claim would conflict with FDA’s findings and be preempted | Court: Breach of express warranty based on voluntary off‑label statements is not preempted but Plaintiffs failed to plead specific warranty statements and causation; claim dismissed with leave to amend |
Key Cases Cited
- Riegel v. Medtronic, Inc., 552 U.S. 312 (federal PMA approval imposes device‑specific requirements that can expressly preempt state law)
- Buckman Co. v. Plaintiffs' Legal Comm., 531 U.S. 341 (private claims premised on enforcement of the FDCA are impliedly preempted)
- Medtronic, Inc. v. Lohr, 518 U.S. 470 (differences in preemption analysis for devices not requiring PMA; discusses PMA rigor)
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading standards; claims must be plausible and legal conclusions are not assumed true)
- Wolicki‑Gables v. Arrow Int'l, Inc., 634 F.3d 1296 (11th Cir.) (explains § 360k parallel‑requirement principle and ‘‘genuinely equivalent’’ test)